Clopidogrel is a prodrug that needs to be converted to its active metabolite (clopi-H4) in two sequential cytochrome P450 (P450)-dependent steps. In the present study, a dynamic physiologically based pharmacokinetic (PBPK) model was developed in Simcyp for clopidogrel and clopi-H4 using a specific sequential metabolite module in four populations with phenotypically different CYP2C19 activity (poor, intermediate, extensive, and ultrarapid metabolizers) receiving a loading dose of 300 mg followed by a maintenance dose of 75 mg. This model was validated using several approaches. First, a comparison of predicted-to-observed area under the curve (AUC) 0-24 obtained from a randomized crossover study conducted in four balanced CYP2C19-phenotype metabolizer groups was performed using a visual predictive check method. Second, the interindividual and intertrial variability (on the basis of AUC 0-24 comparisons) between the predicted trials and the observed trial of individuals, for each phenotypic group, were compared. Finally, a further validation, on the basis of drug-drug-interaction prediction, was performed by comparing observed values of clopidogrel and clopi-H4 with or without dronedarone (moderate CYP3A4 inhibitor) coadministration using a previously developed and validated physiologically based PBPK dronedarone model. The PBPK model was well validated for both clopidogrel and its active metabolite clopi-H4, in each CYP2C19-phenotypic group, whatever the treatment period (300-mg loading dose and 75-mg last maintenance dose). This is the first study proposing a full dynamic PBPK model able to accurately predict simultaneously the pharmacokinetics of the parent drug and of its primary and secondary metabolites in populations with genetically different activity for a metabolizing enzyme.
Introduction
The antiplatelet agent clopidogrel is a prodrug that is metabolized by two main metabolic pathways: an esterase-dependent pathway leading to hydrolysis into an inactive carboxylic acid derivative (85-92% of circulating metabolites) and a cytochrome P450 (P450)-dependent pathway leading to its active metabolite (clopi-H4) (Lins et al., 1999; Kazui et al., 2010; Tuffal et al., 2011; Dansette et al., 2012) . Clopi-H4 is formed in a two-step oxidative process ( Fig. 1 ) mediated by CYP1A2, CYP2B6, CYP2C19, and CYP3A4 (Kazui et al., 2010) . Clopi-H4 leads to inhibition of adenosine diphosphateinduced aggregation by irreversible binding of the platelet P2Y12 receptor (Bhatt and Topol, 2003) .
Polymorphisms of CYP2C19 affect both the pharmacodynamic and pharmacokinetic profiles of clopi-H4, and it has been determined that this isoform is one of the major determinants of interindividual variability in clopidogrel pharmacodynamic and pharmacokinetic responsiveness (Hulot et al., 2006; Kim et al., 2008; Umemura et al., 2008; Mega et al., 2009) . CYP2C19 contribution to the formation of clopi-H4 was confirmed in a randomized crossover study conducted in four balanced CYP2C19-phenotyped metabolizer groups (poor, intermediate, extensive, and ultrarapid metabolizers) (Simon et al., 2011) . The authors of this study also performed a meta-analysis on data from 396 healthy subjects and confirmed that CYP2C19 is the most important polymorphic P450 involved in clopi-H4 formation and antiplatelet response, whereas CYP1A2, CYP2C9, CYP2D6, and CYP3A5 played no significant roles. The in vivo impact of CYP3A4 on clopi-H4 pharmacokinetic variability appears to be minimal as observed after coadministration with CYP3A4 inhibitors such as ketoconazole and dronedarone (Farid et al., 2007; Sanofi, 2014) .
We have previously reported a static model (Boulenc et al., 2012) , which can be generalized for more metabolic steps, to estimate the net contribution of a given polymorphic enzyme to secondary metabolite formation (or its total inhibition). We also used a dynamic model in the Simcyp software to compare predictions with the two types of models. The limitation, as was stated in the publication, was that it was a preliminary physiologically based pharmacokinetic (PBPK) model and that it was not validated, strictly speaking, with a formal comparison between observed and predicted exposure parameters. The aim of the investigation was to use the same metabolized fraction values in the dynamic and static models for comparison of exposure ratios only between the different CYP2C19-phenotyped populations. The PBPK models are models consisting of a physiologically realistic compartmental structure into which input parameters from different sources (e.g., in vitro and in vivo experiments and in silico predictions) can be combined to predict plasma and tissue concentration-time profiles.
PBPK models have gained widespread use as a mechanistic and realistic modeling approach in critical areas of clinical pharmacology, including pediatrics (Edginton et al., 2006; Khalil and Läer, 2011; Barrett et al., 2012; Leong et al., 2012) , pharmacogenetics (Djebli et al., 2009; Yeo et al., 2013) , formulation effect (Jamei et al., 2009; Lukacova et al., 2009) , organ impairment (Thompson et al., 2009; Johnson et al., 2010) , and drug-drug interaction (DDI) (Rostami-Hodjegan et al. 2004; Djebli et al., 2009; Barberan, 2011, 2012; Vieira et al., 2012) . PBPK tools that incorporate interindividual variability of intrinsic factors, such as Simcyp, can improve evaluation of pharmacokinetic interindividual variability and consequently anticipate DDI impact and better determine optimal formulation, dosing regimen, and sampling schemes in the general population as well as in special populations (e.g., renal impaired patients, different ethnic groups, etc.).
In the present study, a dynamic PBPK model was developed and validated for clopidogrel and for its active metabolite clopi-H4, using the specific sequential metabolite module, in the four CYP2C19 phenotype metabolizers groups (poor, intermediate, extensive, and ultrarapid metabolizers).
Materials and Methods

Physiologically Based Pharmacokinetics Model Building
Simcyp algorithms (version 10.20 SE; Simcyp Limited, Sheffield, UK, a CERTARA company) were used to predict clopidogrel and clopi-H4 exposures in CYP2C19 PM (poor metabolizers), intermediate metabolizers (IM ), extensive metabolizers (EM), and ultra-rapid metabolizers (UM).
In addition, a specific module was implemented, through collaboration between Simcyp Limited and Sanofi, and used for the present analysis to enable modeling of a compound with a secondary metabolite. This module is available as free add-on package for all Simcyp users.
Assumptions of the Secondary Metabolite Module. The clopidogrel PBPK model involved the development of a module that incorporated a secondary metabolite formed sequentially from a primary metabolite. The following assumptions were made:
The secondary metabolite is only formed from a primary metabolite of the substrate. The secondary metabolite is available for metabolism and inhibition instantaneously. The substrate is given orally or intravenously and can be administered as a single dose or multiple doses. As for the primary metabolite, the gut transporters kinetic parameters could not be applied for the secondary metabolite. The distribution of the secondary metabolite was described by a minimal PBPK model. As a result, transporter kinetic models (e.g., hepatic transporters), if any, could not be applied. Mutual interactions (competitive inhibition, mechanism-based inhibition, and induction) between the secondary metabolite and other compounds (substrate, the primary metabolite of the substrate, inhibitors, and the primary metabolite of the inhibitor) were considered, as well as autoinhibition, via mechanism-based inhibition and autoinduction.
Implementation of the Secondary Metabolite Module. It was assumed that the formed secondary metabolite was instantaneously available for further elimination (metabolism and excretion) and interactions. MIIS was used to represent the secondary metabolite of the substrate.
The fraction of secondary metabolite escaping first-pass metabolism in the gut, F g-MIIS , could be calculated in the same way as for the primary metabolite:
where Q villi was the villi blood flow, fu gut-MIIS , and CL intG-MIIS were the secondary metabolite unbound fraction in the gut and the total gut intrinsic clearance, respectively. The formation rate of the secondary metabolite in the gut was described by:
where A P was the formation rate of the primary metabolite in the gut, fu gut-P is the unbound fraction of the primary metabolite in the gut, Q gut was the gut blood flow, CL intG-P was the total gut clearance of the primary metabolite, and CL intG-P-n was the nth metabolic pathway of the primary metabolite to form the secondary metabolite. The intrinsic clearances were corrected for nonspecific binding and if V max /Km values were provided, CL intG-P-n was computed as:
where V maxG-P-n and K MP-n were the gut metabolism kinetic parameters of the nth pathway, fu gut-P was the fraction unbound in the gut, and P pv was the primary metabolite concentration in portal vein. The secondary metabolite portal vein concentration was determined using:
where PO F was 0 when the parent drug was given by intravenous route, and 1 when the parent drug was given by oral route. Also, MIIS sys and MIIS pv were the secondary metabolite systemic and portal vein plasma concentrations and F g-MIIS is the secondary metabolite fraction escaping gut metabolism, and Q pv , the portal vein blood flow. The secondary metabolite liver was defined as: 
where Q pv and Q ha were the portal vein and hepatic artery blood flows, Uptake P , and Uptake MIIS were the active uptake into hepatocyte for the primary and secondary metabolites, f ub-P and f ub-MIIS were the unbound fraction of drug in blood of the primary and secondary metabolites, PL iv was the primary metabolite concentration in the liver, and MIIS liv was the liver concentration of the secondary metabolite. Djebli et al.
The secondary metabolite systemic compartment was defined as:
where V d-MIIS was the secondary metabolite volume of distribution at steady-state, Q h was the hepatic blood flow, CL r-MIIS was the secondary metabolite renal clearance and BP MIIS was the secondary metabolite bloodto-plasma ratio, MIIS Liv was the liver concentration of the secondary metabolite, and MIIS sys was the secondary metabolite systemic vein plasma concentration; Depending on the extent of sequential metabolism, a certain amount of the secondarily formed metabolite will go to systemic circulation.
Input Data
Simcyp model was set up using clopidogrel and its metabolites (i.e., 2-oxoclopidogrel, the primary P450-dependent metabolite, and clopi-H4, the 
9.16 fu mic 0.0011 fa, fraction absorbed; fu p , unbound fraction in plasma; fu mic , unbound fraction in microsomes; Ka, first-order rate constant; K i and K inact , mechanism-based inactivation parameters; P eff , effective permeability in human; Vss, steady state.
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Physicochemical Parameters. As physicochemical input parameters, the molecular weight, the chemical nature, the Pka, and the LogP values were used for clopidogrel, 2-oxo-clopidogrel, and clopi-H4.
Absorption. The absorption process was described for clopidogrel only. The first-order absorption model was selected with a fraction absorbed (fa), a firstorder rate constant (Ka), and an effective permeability (P eff ) in human were used as input parameters. The formulation was considered as a solution.
Distribution. Two PBPK distribution models were available in Simcyp: the minimal and the full PBPK models. The minimal PBPK model can be described as a "lumped" model that has only three compartments, when there is no singleadjusting compartment (i.e., peripheral compartment), predicting the systemic, portal vein, and liver concentrations. The full PBPK distribution model proposed a number of time-based differential equations to simulate the concentrations in various organ compartments: blood (plasma), adipose, bone, brain, gut, heart, kidney, liver, lung, muscle, skin, and spleen. The interindividual variability of tissue volume was estimated taking account of age, sex, weight, and height. The distribution is assumed to be perfusion-limited, using the full PBPK model, unless the membrane transporters are taken into account, whereby permeability-limited distribution is handled in the liver, kidney, and brain. For the current analysis, the full PBPK distribution model was selected for clopidogrel, and the minimal PBPK model was selected for 2-oxo-clopidogrel and for clopi-H4. The volumes of distribution at steady-state (Vss) were 0.217, 0.10, and 0.23 l/kg for clopidogrel, 2-oxo-clopiogrel, and clopi-H4, respectively. These values were predicted using the model proposed by Rodgers and Rowland (Rodgers et al., 2005a, b; Rowland 2006, 2007) , with the exception of 2-oxoclopidogrel, for which the sensitivity analysis model was used to refine this value on the basis of its impact on the observed clopidogrel and clopi-H4 exposures [maximum plasma concentration (C max ) and area under the curve (AUC)]. The blood-to-plasma ratio was predicted using the model proposed by Uchimura et al. (2010) : 0.72, 1.00, and 0.82 for clopidogrel, 2-oxo-clopidogrel, and clopi-H4, respectively. The unbound fraction in plasma (fu p ) was set to 0.02 for clopidogrel as stated in the analytical dossier and to 0.031 and 0.018 for 2-oxo-clopidogrel and clopi-H4, respectively, using the model proposed by Lobell and Sivarajah (2003) .
Elimination. For clopidogrel metabolism, enzyme kinetics information using human recombinant P450 isoforms was selected. The maximum velocity of the metabolizing enzyme (V max) , and Michaelis-Menten coefficient value (K M ) from Kazui et al. (2010) were used. The unbound fraction in human hepatic microsomes (fu mic ) of 0.015 was predicted using the QSAR model published by Gao et al. (2008) , in a first step, and refined using the sensitivity analysis module on the basis of observed clopidogrel and clopi-H4 exposures in a second step. Moreover, an additional systemic clearance of 600 l/h was considered, representing the esterase-mediated clearance using the retrograde model (about 90% of clopidogrel total clearance).
The enzyme kinetic information (V max and K M ) from Kazui et al. (2010) using human recombinant P450 isoforms was also used for 2-oxo-clopidogrel. Moreover, an additional clearance of 50 ml/min per milligram was considered for 2-oxo-clopidogrel, representing the esterase-mediated clearance (about 50% of the total 2-oxo-clopidogrel clearance). An active uptake into hepatocytes of 2 was set for 2-oxo-clopidogrel using the sensitivity analysis module.
Regarding clopi-H4, an in vivo clearance of 500 l/h was programmed into Simcyp. This value represented the immediate direct irreversible binding of this active metabolite to platelets.
Dronedarone PBPK Model. The dronedarone Simcyp model has been previously developed and validated for a large range of doses (200-1600 mg BID). The input parameters are detailed in Table 2 .
This model accurately predicted the pharmacokinetics of dronedarone and correctly took into account the nonlinearity of dronedarone pharmacokinetics (Fig. 2) . This nonlinearity resulted from the moderate mechanism-based inhibition of CYP3A4, which is the main isoform involved in dronedarone clearance itself. The main purpose of the dronedarone model was its application as a guide for dose selection in pediatrics. This model was also used to evaluate the feasibility of 
Simcyp Simulations
The simulations were performed using four virtual populations (10 trials of 10 individuals each) of 100 healthy volunteers aged between 20 and 50 with a male/female ratio of 50/50, in fasted condition, representing PM-, IM-, EM-, and UM-CYP2C19 individuals. The number of virtual subjects (10 trials of 10 subject in each trial) was selected on the basis of the subject number in study 1 (10 subjects in each CYP2C19-phenotyped group) to optimize the relevance of the comparison with observed values at the model validation step.
The difference between these four CYP2C19-phenotyped groups resulted mainly from mean liver CYP2C19 abundance. For EM individuals, the mean liver abundance of CYP2C19 was set in the Simcyp library to 14 pmole/mg of protein, whereas it was defined as 0 pmole/mg for PM individuals. Regarding IM and UM individuals, the liver abundances of CYP2C19 were set to 10 and 18 pmole/mg, respectively, after repeated simulations using a conditional sensitivity analysis with mean value for IM individuals ranging between 0 and 14 pmol/mg (between PM and EM individuals) and for UM individuals higher than 14 pmol/mg (higher than EM individuals).
A customized design similar to that of study 1 was used, with a 5-day treatment duration: a loading dose of 300 mg clopidogrel at day 1 and a maintenance dose of 75 mg once daily clopidogrel from day 2 to day 5.
The simulations could be performed in Simcyp using either the "PK/PD parameters" or the "PK/PD profiles" options. The PK/PD parameters option was the only way to estimate the relative enzyme contribution (static modeling). This option excludes time-and, in some cases, concentration-dependent phenomena. The PK/PD profiles options provided time-and concentrationdependent predictions. The inter-and intramoieties interactions (metabolite, inhibitor, inducer, effect of the substrate on its own metabolism) were also taken into account, as well as the organ parameters (e.g., changes in enzymes synthesis or degradation rates following administration of an inducer and/or a mechanism-based inhibitor).
In the present analysis, the PK/PD parameters option was used to estimate the relative enzyme contribution for both clopidogrel and 2-oxo-clopidogrel metabolism, and the PK/PD profiles option was used to predict the PK profiles of the compounds in the different CYP2C19-phenotyped groups.
Clinical Trials
Two clinical studies were used for model validation purposes in the present analysis. The first one aimed at validating the contribution of CYP2C19 in clopidogrel metabolism and clopi-H4 formation. The second study aimed at validating the model in terms of CYP3A4-based DDI.
The first clinical study (study 1) was conducted to compare clopidogrel and clopi-H4 in four CYP2C19-defined metabolizer groups. This single-center, randomized, placebo-controlled, two-treatment, two-period crossover study in four CYP2C19-defined metabolizer groups (PM, IM, EM, and UM) was conducted to determine whether CYP2C19 polymorphisms affected the pharmacokinetics of clopidogrel and clopi-H4 after clopidogrel oral administration of 300-mg loading dose followed by 75 mg for 4 days or 600-mg Fig. 3 . Mean predicted contribution of P450 isoforms and esterase (additional clearance) to clopidogrel (A) and to 2-oxoclopidogrel (B) metabolism in CYP2C19-extensive metabolizers.
TABLE 3
Observed-versus-predicted ratio estimates (90% CI) of C max and AUC 0-24 for clopidogrel and clopi-H4 without and with dronedarone coadministration (400 mg BID) at day 1 (300-mg loading dose) and at day 5 (75-mg maintenance dose) (Simon et al., 2011) . The number of subjects was 40 (10 per group).
The second clinical study (study 2) was conducted to evaluate the impact of dronedarone, a moderate CYP3A4 inhibitor, on the pharmacokinetics of clopidogrel and clopi-H4 pharmacokinetics. This was a randomized, singlecenter, double-blind, placebo-controlled, repeated-dose, two-treatment twoperiod, two-sequence crossover pharmacokinetic interaction study conducted in France. The two treatment periods, separated by a 7-day washout period, were as follows: repeated doses of 400 mg BID dronedarone or placebo (for 14 days) on repeated doses of clopidogrel (300-mg loading dose followed by 75-mg maintenance dose for 4 days) started the 10th day after dronedarone initiation. Dronedarone was administered for 9 days before clopidogrel initiation to achieve steady-state pharmacokinetic conditions. Regardless of the sequence, a washout duration between of the two periods was at least 7 days to ensure that platelet aggregation returned to baseline during the $17 days between the last clopidogrel administration (day 14) in the first treatment period and the loading dose of clopidogrel (day 10) in the second treatment period. Healthy male subjects 18-65 years of age were eligible for enrollment if they provided informed consent; had a body weight of 50-95 kg, body mass index of 18-28 kg/m 2 ; and no contraindication to clopidogrel and dronedarone. Only CYP2C19 EM individuals were considered in this analysis. 
Downloaded from
Clopidogrel and clopi-H4 analyses: plasma samples for pharmacokinetic assessment of unchanged clopidogrel and clopi-H4 were collected after loading dose and last maintenance dose of each of the two periods at T0 (time of clopidogrel administration) and at time points (in hours) T0.25, T0.5, T1, T1.5, T2, T3, T4, T6, T10, T16, and T24 under conditions already described for study 1 (Simon et al., 2011) . Clopidogrel and clopi-H4 plasma concentrations were assayed by Sanofi (Bridgewater, NJ; Malvern, PA; and Montpellier, France), using validated liquid chromatography-tandem mass spectrometry with lower limits of quantification of 5 pg/ml and 0.5 ng/mL, respectively (Tuffal et al., 2011) .
C max and area under the plasma concentration-versus-time curve from T0 to T24 using the trapezoidal rule (AUC 0-24 ) were calculated using noncompartmental techniques using PKDMS Version 2.0, incorporating WinNonlin Professional Version 5.2.1 (Pharsight, Mountain View, CA).
Validation of the PBPK Model
Comparison of Predicted-to-Observed Clopidogrel and Clopi-H4 AUC Values. The predicted AUC 0-24 values of clopidogrel and clopi-H4, using the PBPK model, at loading dose (day 1) and maintenance dose (day 5) were compared with those observed in study 1. This comparison was performed for each CYP2C19-phenotyped group.
As previously mentioned, for each simulation (i.e., each CYP2C19-phenotyped group), 10 trials of 10 virtual individuals in each trial were generated. The median AUC 0-24 value and error bar of the group of "real" subjects was presented together with the median and error bar of each virtual trial. This representation allowed both the predicted interindividual variability and intertrial variability to be well evaluated and confirmed that the group of "real" patients behaved as one of the virtual trials.
Visual Predictive Check. A visual predictive check (VPC) was adapted to PBPK and performed to allow a graphical qualification of the clopidogrel/2-oxo-clopidogrel/clopi-H4 Simcyp model. This evaluation method of the model's predictive performance by comparing the predictions to clinical data were described as the reference at the 2012 FDA Pediatric Advisory Committee (US Food and Drug Administration, 2012). Briefly, to graphically validate the model's predictability, the 50th (median), 5th and 95th percentiles of predicted concentrationtime profiles (obtained from the Simcyp simulations of 100 generated virtual individuals for each CYP2C19-phenotyped group and for each compound) were presented with the observed data obtained in study 1.
Validation Based on DDI prediction. The last validation was performed on the basis of DDI predictions using a previously developed and validated dronedarone Simcyp model, given the fact that dronedarone is a P450-dependent substrate and is a CYP3A4 mechanism-based inhibitor (MBI) (US Food and Drug Administration, 2009 ). This validation was performed by the comparison of the Simcyp predictions to observed values (from clinical study 2), with or without dronedarone coadministration, on clopidogrel and on the active metabolite clopi-H4 plasma pharmacokinetics.
Results
Predicted Contribution in Clopidogrel and 2-Oxo-Clopidogrel Metabolism. The Simcyp simulation using the "PK/PD parameters" option with 100 virtual CYP2C19-EM individuals resulted in mean dmd.aspetjournals.org clopidogrel metabolism contributions for CYP1A2, CYP2B6, CYP2C19 and additional systemic clearance as presented in Fig. 3A , and in mean 2-oxo-clopidogrel metabolism contributions for CYP2B6, CYP2C9, CYP2C19, and CYP3A4 and additional clearance as presented in Fig. 3B .
The mean contribution of non-P450-mediated systemic clearance, i.e., mainly esterase-dependent hydrolysis to the overall clopidogrel clearance was about 90.2%. Specifically regarding P450-mediated oxidative clearance of clopidogrel and representing about 10% of overall clearance, predicted relative mean contributions were of 29.0% for CYP1A2, 22.4% for CYP2B6, and 48.6% for CYP2C19.
For 2-oxo-clopidogrel metabolism, mean contribution of non-P450-mediated clearance to the overall 2-oxo-clopidogrel clearance was about 50.7%. Specifically regarding P450-mediated oxidative clearance of 2-oxo-clopidogrel, Simcyp predicted relative mean contributions of 39.0% for CYP2B6, 6.47% for CYP2C9, 21.1% for CYP2C19, and 33.5% for CYP3A4. These predictions are consistent with those published by Kazui et al. (2010) .
Comparison of Predicted-to-Observed Clopidogrel and Clopi-H4 AUC 0-24 Values. The predicted AUC 0-24 values of clopidogrel and clopi-H4, using the PBPK model, at loading dose (day 1) and maintenance dose (day 5) were compared with those observed in study 1. This comparison was performed for each CYP2C19-phenotyped group. The median AUC 0-24 value and error bar of the group of observed subjects was presented together with the median and error bar of each virtual trial. In addition, the corresponding global median and 5th and 95th percentiles for each dose in each CYP2C19-phenotyped group obtained from the 100 virtual subjects taken together were presented. In addition to allowing a comparison of predicted to observed median AUC 0-24 values, this representation provided an accurate evaluation of both predicted interindividual and intertrial variability. This is also a way to confirm that the group of observed patients (n = 10) behaved as one of the virtual trials (n = 10 each).
Figures 4 and 5 present the results for clopidogrel 300-mg loading (day 1) and 75-mg maintenance doses (day 5), respectively. Figures 6 and 7 are the results for clopi-H4 at these doses.
These figures showed the good predictive performance of the Simcyp model for both clopidogrel and clopi-H4, whatever the treatment period (for both loading and maintenance doses) and whatever the CYP2C19-phenotyped group.
Visual Predictive Check. The VPC was adapted to PBPK and performed to allow a graphical qualification of the Simcyp model from day 1 (300-mg loading dose) to day 5 of treatment (75-mg maintenance dose), for clopidogrel and for clopi-H4 in each CYP2C19-phenotyped group. The results are presented in Fig. 8 for clopidogrel and Fig. 9 for clopi-H4. These results, obtained from the 100 virtual individuals for each CYP2C19-phenotyped group, for both clopidogrel and clopi-H4, confirmed the accuracy of the predictions and the good CYP2C19 contribution in both metabolic steps (clopidogrel to 2-oxo-clopidogrel and 2-oxo clopidogrel to clopi-H4). In addition, these figures confirmed the accurate estimation of the interindividual variability for both compounds.
Model Qualification on the Basis of DDI Prediction. This model qualification on the basis of DDI prediction uses a previously developed and validated dronedarone Simcyp model (see Table 2 and Fig. 2) .
As previously mentioned, study 2 was conducted to evaluate the impact of dronedarone coadministration (400-mg BID repeated doses from day 9 to day 5) on the pharmacokinetics of clopidogrel and clopi-H4 pharmacokinetics (300-mg clopidogrel loading dose at day 1 followed by 75 mg from day 2 to day 5), since dronedarone is a moderate CYP3A4 MBI. The Simcyp simulations were performed on the basis of the same design and similar population (healthy CYP2C19-EM individuals) study 2 to make the comparison the most reliable. The observed and predicted ratio estimates and 90% confidence intervals are presented in Table 3 and the observed and predicted clopi-H4 exposures are presented in Table 4 .
Regarding clopidogrel, this comparison confirmed the absence of any DDI on clopidogrel when coadministered with dronedarone. The observed ratio estimates ranged between 0.89 and 1.03 and predicted values ranged between 1.00 and 1.01. When looking at the clopi-H4 exposures (see Table 4 ), the predicted C max values were very similar to the observations when clopidogrel was administered without dronedarone comedication and slightly underestimated when coadministered with dronedarone (for both day 1 and day 5). On the contrary, the predicted AUC 0-24 seemed to be slightly overestimated when clopidogrel was administered without dronedarone and very close to observations when coadministered with dronedarone (also observed for at both day 1 and day 5). Overall, the predicted interindividual variability on clopi-H4 exposures (56.4-66.2%) was close to the observations (40.0-80.7%).
Discussion
This is the first study proposing a full dynamic PBPK model able to accurately predict simultaneously the pharmacokinetics of the parent drug, its primary and secondary metabolites, in populations with genetically different activity for a metabolizing enzyme. This PBPK dmd.aspetjournals.org model was developed for clopidogrel, its primary metabolite 2-oxoclopidogrel, and its secondary active metabolite clopi-H4. The model qualification was performed on the parent drug clopidogrel and on clopi-H4 whatever the treatment period (loading or maintenance doses) for each CYP2C19-phenotyped group (PM, IM, EM, and UM).
The model was not validated for 2-oxo-clopidogrel because of the absence of plasma concentrations for this metabolite. The 2-oxo-clopidogrel plasma concentrations were not assayed because of the weak stability and of the fleeting property of this metabolite.
The PBPK model was built using an approach integrating all of the available physicochemical and in vitro information of the three compounds, gathered via the enzyme kinetic parameters that govern the two metabolic steps.
The observed data from two clinical studies were used for model qualification: 1) the first study with well-balanced genetic polymorphic populations (CYP2C19-PMs, -IMs, -EMs, and -UMs), on the basis of the important CYP2C19 involvement in both metabolic steps, and 2) the second study with or without dronedarone coadministration for DDI prediction purpose, given that dronedarone is a moderate CYP3A4 MBI and that CYP3A4 is involved in the second step of clopidogrel metabolism, i.e., 2-oxo-clopidogrel to clopi-H4. Three qualification methods were used for this PBPK model: the comparison of observed-to-predicted AUC 0-24 coupled with an estimation of the variability, the VPC method, on the basis of a visual inspection of the predictive performance of the model, and the last method on the basis of DDI prediction.
The first qualification method is presented in Figs. 4 and 5 for clopidogrel and in Figs. 6 and 7 for clopi-H4 on the basis of a comparison of the observed median AUC 0-24 values (and the corresponding variability) in each CYP2C19-phenotyped group (with n = 10 for each group) to the predicted values of 10 virtual trials (10 individuals in each trial). This dmd.aspetjournals.org representation allowed, in addition to evaluating the predictive performance of the model regarding median values, estimation of the interindividual and intergroup variability. This method allowed validation of the model for both clopidogrel and clopi-H4 in each CYP2C19-phenotyped group, whatever the treatment period, and clearly showed that the clinical study, in terms of AUC 0-24 , behaved as one of the virtual trials.
The second qualification method was developed on the basis of the adaptation of VPC method to PBPK. Classically, the VPC method is performed to validate a model developed using the population approach (population pharmacokinetics and pharmacodynamics), where hundreds of simulations were launched once the final model was built, and at the end the observations were visually compared with the statistics of the predictions (Holford 2005; Karlsson and Holford, 2008; Post et al., 2008) . This method is uses as a basis the presentation of the observed concentrations on a "time-versus-concentrations" plot on which were superimposed the 5th, 50th (median), and 95th percentiles of the predictions obtained from 100 virtual individuals. A plot was presented for each compound and for each CYP2C19-phenotyped group (Fig. 8 for clopidogrel and Fig. 9 for clopi-H4 ). In the present study, this method confirmed the good predictive performance of the PBPK model.
The complexity of clopidogrel pharmacokinetics, linked to the metabolic cascade with many metabolic enzymes involved (different P450s and esterases), was a strong incentive to perform a model qualification on the basis of DDI prediction and on the comparison of ratio estimates of C max and AUC 0-24 of clopidogrel and clopi-H4, with and without dronedarone coadministration. A PBPK model previously developed and validated accurately predicted the pharmacokinetics of dronedarone and correctly accounted for the nonlinearity of dronedarone pharmacokinetics resulting from the moderate mechanism-based inhibition of CYP3A4, which is itself the main isoform involved in dmd.aspetjournals.org dronedarone clearance. Regarding clopidogrel, this comparison confirmed the absence of any DDI interaction on C max and AUC 0-24 of clopidogrel when coadministered with dronedarone. On the other hand, for the active metabolite clopi-H4, the predicted ratio estimates were unexpectedly slightly underestimated. There are some hypotheses that could explain this underestimation. The first one would be an overestimation of the impact of dronedarone CYP3A4 inhibition via inaccurate mechanism-based inactivation input parameters (K I /K inact ) and/or CYP3A4 turnover (K deg ) values in the Simcyp population library. This hypothesis was evaluated since the K deg value used in this library (0.0077 hour
21
) was discussed (Rowland-Yeo et al., 2011) , suggesting that the use of a higher value (0.0193 hour
) resulted in less bias and greater precision in the predictions. At the end, this hypothesis was improbable since the dronedarone model was well validated using a large range of doses (from 200 to 1600 mg BID) and accurately predicted the CYP3A4 saturation attributable to mechanism-based inhibition. The second hypothesis would be an overestimation of CYP3A4 contribution to 2-oxo-clopidogrel metabolism. This idea is debatable given that the clopidogrel model was well validated for the four CYP2C19-phenotyped groups, suggesting that the contribution of CYP2C19 was well documented and consistent with the observed values. Given that P450 isoforms other than CYP2C19 and CYP3A4 were involved in 2-oxo-clopidogrel metabolism, a clinical study to validate this hypothesis would be of interest.
This work is the first study accurately describing the pharmacokinetics of a drug and its sequential metabolite using the PBPK approach in different phenotypic groups. This can be considered as the first step in building up a PBPK-PD model able to predict the therapeutic effect in different subpopulations and/or different clinical conditions (Chetty et al., 2014) .
